Literature DB >> 4068606

[Cardiovascular effect of the antidiuretic hormone arginine vasopressin].

W Rascher.   

Abstract

The two major biological actions of vasopressin are antidiuresis and vasoconstriction. The antidiuretic action of low concentrations of vasopressin is well established and concentrations 10 to 100 times above those required for antidiuresis elevate arterial blood pressure. Antidiuresis is mediated by V2-receptors at the kidney, whereas vasopressin constricts arterioles by binding at V1-receptors. Pharmacological effects of specific antagonists of the vasoconstrictor activity of vasopressin (vascular or V1-receptor antagonists) are presented. Low concentrations of vasopressin do have significant hemodynamic effects. Physiological concentrations of vasopressin cause vasoconstriction and elevate systemic vascular resistance. In subjects with intact cardiovascular reflex activity, however, cardiac output falls concomitantly and blood pressure therefore does not change. In animals with baroreceptor deafferentation or in patients with blunted baroreceptor reflexes (autonomic insufficiency) a rise in plasma vasopressin causes vasoconstriction and an increase in blood pressure, because cardiac output does not fall under these conditions. Vasopressin contributes substantially via increase in systemic vascular resistance to maintain blood pressure during water deprivation. During hemorrhage and hypotension vasopressin has a major role to restore blood pressure. In experimental hypertension vasopressin contributes to the development and maintenance of high blood pressure in DOCA, but not in genetic hypertensive rats. The role of vasopressin in human hypertension is not yet clear. Vasopressin in extrahypothalamic areas of the brain affects circulatory regulation by interaction with central cardiovascular control centers. The exact mechanism of how vasopressin is involved in central regulation of blood pressure remains to be established. In contrast to our previous opinion vasopressin is a vasoactive hormone also at low plasma concentrations. Its cardiovascular action is more complex than previously assumed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4068606     DOI: 10.1007/BF01737635

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  83 in total

1.  [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin.

Authors:  J J Nestor; M F Ferger; V du Vigneaud
Journal:  J Med Chem       Date:  1975-03       Impact factor: 7.446

Review 2.  Synthetic analogs of oxytocin and the vasopressins.

Authors:  W H Sawyer; M Manning
Journal:  Annu Rev Pharmacol       Date:  1973       Impact factor: 13.820

3.  Regional vascular effects of vasopressin: plasma levels and circulatory responses.

Authors:  P G Schmid; F M Abboud; M G Wendling; E S Ramberg; A L Mark; D D Heistad; J W Eckstein
Journal:  Am J Physiol       Date:  1974-11

4.  Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension.

Authors:  J Möhring; K Glänzer; J A Maciel; R Düsing; H J Kramer; R Arbogast; J Koch-Weser
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

5.  Stimulus-response coupling in neurohypophysial peptide target cells.

Authors:  S Jard; J Bockaert
Journal:  Physiol Rev       Date:  1975-10       Impact factor: 37.312

6.  Cardiovascular, sympathetic, and renin-angiotensin system responses to hemorrhage in vasopressin-deficient rats.

Authors:  R L Zerbe; G Feuerstein; D K Meyer; I J Kopin
Journal:  Endocrinology       Date:  1982-08       Impact factor: 4.736

7.  [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.

Authors:  J Lowbridge; M Manning; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1978-03       Impact factor: 7.446

Review 8.  Sites of hormone action in the mammalian nephron.

Authors:  F Morel
Journal:  Am J Physiol       Date:  1981-03

9.  Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

Authors:  M Manning; A Olma; W A Klis; A M Kolodziejczyk; J Seto; W H Sawyer
Journal:  J Med Chem       Date:  1982-01       Impact factor: 7.446

10.  Blood pressure and heart rate responses to microinjection of vasopressin into the nucleus tractus solitarius region of the rat.

Authors:  H Matsuguchi; F M Sharabi; F J Gordon; A K Johnson; P G Schmid
Journal:  Neuropharmacology       Date:  1982-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.